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The genomic sequences of viruses that are highly mutable and cause chronic infection tend 
to diverge over time. We report that these changes represent both immune-driven selection 
and, in the absence of immune pressure, reversion toward an ancestral consensus. Sequence 
changes in hepatitis C virus (HCV) structural and nonstructural genes were studied in a 
cohort of women accidentally infected with HCV in a rare common-source outbreak. We 
compared sequences present in serum obtained 18–22 yr after infection to sequences 
present in the shared inoculum and found that HCV evolved along a distinct path in each 
woman. Amino acid substitutions in known epitopes were directed away from consensus in 
persons having the HLA allele associated with that epitope (immune selection), and toward 
consensus in those lacking the allele (reversion). These data suggest that vaccines for 
genetically diverse viruses may be more effective if they represent consensus sequence, 
rather than a human isolate.
 
A virus capable of genetic variation and of
causing chronic infection will evolve to opti-
mize its fitness in each host, a process which is
the net sum of immune recognition (positive
selection) and functional constraint on replica-
tion (negative selection). Because an estimated
10
 
12
 
 virions are produced each day through
an error-prone, nonproofreading NS5B RNA
polymerase, hepatitis C virus (HCV) is especially
capable of viral evolution (1, 2). However, we
previously showed that evolution is not driven
by replication alone. In the acute phase of in-
fection before adaptive immune responses (but
after weeks of replication supporting a viral
RNA level of more than 10
 
5
 
 IU/ml), the same
major viral variant was detected in each of a serial
passage of eight chimpanzees (3). In contrast, the
sequence of envelope genes, particularly HVR1,
changes in virtually all humans who have been
persistently infected (including the source of
the inoculum passaged through this chimpanzee
lineage [4]), a notable exception being persons
with attenuated humoral immune responses
(agammaglobulinemia), who have been shown
to have reduced variability in HVR1 (5). Longi-
tudinal studies of chimpanzees experimentally
infected with HCV have revealed that amino
acid replacements in immunodominant CD8
 
 
 
T cell epitopes presented on MHC class I in an
allele-restricted manner contribute to viral per-
sistence (6). Thus, we hypothesized that the net
evolution of HCV would demonstrate both
functional constraint (reversion of sequences
toward consensus) as well as positive pressure
(and thus reveal immunodominant epitopes).
Although it required that persons be in-
fected with the same inoculum, it was possible
to test this hypothesis because between May
1977 and November 1978 over 500 women
were inadvertently infected with HCV from a
single acutely infected source, as a result of
treatment with contaminated anti-D immune
globulin (7). In a single amplicon, a 5.2-kb
cDNA spanning 5
 
 
 
UTR through the NS3–
NS4A junction was cloned from serum collected
from 22 women 18–22 yr after infection, as
well as in two specimens of frozen plasma from
the inoculum donor.
 
RESULTS AND DISCUSSION
 
HCV envelope sequence from the inoculum
clustered near the base of the clade formed by se-
quences from the chronically infected women
(Fig. 1), and the entire anti-D cohort clade was
clearly distinct from all other sequences in avail-
able databases (excluding those from this out-
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Figure 1. Phylogenetic analysis of HCV 18–22 yr after common-
source outbreak. (A) Phylogenetic tree of 5.2-kb sequence alignment 
placing outbreak clade (*) in context with reference sequences for all 
major subtypes. (B) Detailed analysis of the outbreak clade, using 10 
cDNA clones from each study subject to obtain the sequence of a 698-nt 
region spanning the E1–E2 junction. The label “inoculum” indicates 20 
clones from inoculum source plasma (10 each from 2 specimens), and a 
full-length clone (AF313916) obtained in an independent study of this 
material using smaller amplicons. For both trees, numbers at nodes are 
bootstrap values, indicating the percentage of 1,000 permuted trees that 
supported the presence of that node. Bootstrap support was 100% for 
each of the major clades in A; in B, only bootstrap values  80% are 
shown, and values for nodes within a study subject’s clade were omitted 
for clarity. Boxes highlight two subjects whose sequences were segre-
gated into two separate clades. 
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break), consistent with the previously reported clinical history
of common-source infection from an acutely infected donor
(7). Nonetheless, HCV sequences in each woman diverged
along distinct paths. Recipient sequences differed from inocu-
lum sequences at a median (range) of 51 (35–73) nucleotide
sites and 23 (15–38) amino acid sites in envelope genes (E1 and
E2), and 72 (12–136) nucleotide sites and 18 (8–28) amino acid
sites in nonenvelope genes (Core, p7, NS2, and NS3).
There was strong evidence of negative selection (sequence
conservation) at some loci. Not only were there regional dif-
ferences in sequence divergence in all genes, but there were
also marked regional differences in the relative proportion of
nonsynonymous (amino acid-changing) and synonymous (si-
lent) changes (Fig. 2). Overall, the highest rate of nonsynony-
mous change was observed in the E2 gene, followed by NS2,
p7, E1, NS3, and Core. Synonymous substitution rates were
consistently higher than nonsynonymous rates for all genes,
suggesting strong negative selection is a consistent feature of
chronic HCV infection. HVR1 sequences were highly diver-
gent at many sites, but constrained at others (8, 9).
At other loci, these data also reflect strong positive selec-
tion. For example, in HVR1when the amino acid of the in-
oculum matched the consensus for that viral subtype, resi-
dues either did not change or changed in an apparently
“sporadic” fashion (risk of finding the residue in recipients
was not different than finding the residue in the inoculum,
indicated by near-zero height of the sequence logo in Fig. 2,
with additional detail in Fig. S1). In contrast, when the
amino acid in the inoculum differed from the consensus,
there was convergent evolution toward consensus (residue
was found over two times more often in the recipients than
in the inoculum; Fig. 2). For example, 16 of the 22 women
had replaced H in the inoculum with R at position 394, 12
replaced A with T at 396, 11 replaced L with F at 399, and
16 replaced T with S at 401. Four women had all four of
these changes, not significantly different from the expected
frequency of 3.2, indicating that these changes occurred in-
dependently. Interpreted in recognition of the thesis that vi-
ral sequence evolves to optimize fitness and the infinitesimal
likelihood that these same amino acid substitutions occurred
Figure 2. HCV divergence and convergence after a common-source 
outbreak. The upper panel shows a sliding-window analysis of nonsynon-
ymous (red) and synonymous (blue) variation, calculated by comparing the 
mean pairwise distance between the inoculum (2 cDNA clones obtained 
from two inoculum source plasma specimens obtained 1 wk apart in 
1977) to 44 clones (2 per study subject) obtained from chronically infected 
women 18–22 yr after exposure, in a sliding window 20 codons wide, 
moving in 1-codon increments, generated using VarPlot. Horizontal bars 
indicate average distance for each gene region. The lower panel is com-
posed of sequence logos displaying the variability in HVR1 (the region 
indicated by dashed lines in the upper panel), with numbers indicating 
position relative to the H77 polyprotein. The first three rows show the 
subtype 1b reference sequences, inoculum sequences (20 clones from 
2 plasma specimens obtained 1 wk apart), and 220 recipient sequences 
(10 per study subject) respectively, with the height of each single-letter 
amino acid code proportional to its frequency. The residue at the top of 
the stack in each position is the most-frequently observed, and hence the 
consensus residue, at that position. The fourth row shows differences 
between the amino acid frequencies in the recipient sequences versus the 
inoculum sequences as a type 2 logo, in which the height of each amino 
acid is determined by the log2 relative risk of observing it, with the scale 
indicated. Empty spaces indicate a distribution highly similar to the inocu-
lum distribution, because the logarithm of a relative risk of one is zero. 
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by chance in each of the women, these data suggest that the
sequences converged to a more fit state.Further, it is likely
that prior evolution of the inoculum sequence to optimize
its fitness in the original host resulted in changes that dimin-
ished its fitness in the subsequent hosts.
Rather than convergent evolution, these results might
have been due to shared selection and then divergence (at
other sites) from a rare variant that we did not detect in the
inoculum. We did detect one clone (clone #5) among 20 in
the inoculum material that carried the RxTxxFxS motif at
positions 394–401, but it was highly divergent from all other
sequences described here, as evident from its position in the
phylogenetic tree (Fig. 1 B), and therefore less likely than
the other 19 sequences to represent the founder strain for
these women. Although it is possible that a less divergent
RxTxxFxS clone was present in the inoculum at very low
frequency, shared selection of such a rare variant would sup-
port the same conclusion.
Because HVR1 is a potential target of both humoral and
cellular immunity and the precise recognition motifs remain
difficult to identify due to the extreme variability, further
examination of positive selection was focused on non-
envelope genes, and in particular, on known MHC class
I–restricted epitopes. Consistent with immune selection hy-
pothesis, the number of changes in sites of known epitopes
associated with specific class I alleles was significantly greater
than the number of changes in other sites (RR
 
 
 
1.6, P 
 
 
 
0.05), and greater than what was found in that same site for
persons who did not possess the allele (Table I, with detail
for all epitopes in Fig. S2). For HLA B*35, changes in
epitopes were observed only in women having that allele,
and for B*37, sequence changes were 8.5 times as likely to
occur in an epitope associated with an allele in women hav-
ing the allele as compared with those that lacked it (P 
 
 
 
0.001). An example of such an epitope is shown in a 38–
amino acid region that spans an HLA A2 motif (Fig. 3, A
and B). Mutations from R to K were noted at position 1397
outside the A2 epitope, and mutations from G to S were
noted within the epitope in 8 and 6 of 22 women, respec-
tively. However, whereas R to K mutation was noted in a
similar percentage of A2-positive and A2-negative women
(41.7% vs. 30.0%, P 
 
  
 
0.10), all G to S mutations were ob-
served in A2-positive women (P 
 
  
 
0.015), consistent with
immune escape as has been observed in the simian immuno-
deficiency virus macaque model (10) and chimpanzees in-
fected with HCV (6).
As seen with envelope sequences, the opposite effect was
observed in other alleles. For alleles A*01 and B*08, se-
quence changes were 0.2 and 0.4 times as likely to occur in
an epitope restricted by an allele in women having the allele
as compared with those who lack it (Table I). In fact, the
R1397K substitution that was described above in both A2-
positive and -negative women, only occurred in women
who were not HLA B*08 positive, although the apparently
A2-restricted G1409S substitution occurred in both B*08-
positive and -negative women (Fig. 2 C).
Collectively, these findings indicate that HCV sequence
change is a nonrandom process that reflects negative selection
(change is disadvantageous) as well as positive selection.
Moreover, we find evidence that positive selection represents
both the direct effect of pressure applied by immune responses
in the current host (in this case, HLA class I–restricted CD8
 
 
 
cytotoxic T lymphocytes) as well as reversion of sequence to-
ward a consensus, as we saw with envelope sequences.
To independently evaluate this paradigm, we compared
the amino acid sequences of these women with an HCV 1b
consensus sequence. For the epitopes that showed evidence
of HLA class I–restricted positive selection (a significantly in-
 
Table I. 
 
Epitope changes according to the presence of restricting HLA alleles
 
Allele Subjects with allele  Epitopes
Allele present Allele absent Relative risk of change 
(allele present versus 
absent) p-value
 
Epitope changes/sites  Epitope changes/sites
 
n n (%) (%)
 
A
 
*
 
01 11 1 2/198 (1.0) 10/198 (5.1) 0.2 0.019
A
 
*
 
02 13 13 39/3,198 (1.2) 18/2,214 (0.8) 1.5
 
 
 
 
 
0.10
A
 
*
 
03 9 4 8/648 (1.2) 18/936 (1.9) 0.6
 
 
 
 
 
0.10
A
 
*
 
11 3 3 6/162 (3.7) 45/1,026 (4.4) 0.8
 
 
 
 
 
0.10
A
 
*
 
24 1 2 0/36 (0.0) 3/756 (0.4) 0
 
 
 
 
 
0.10
B
 
*
 
07 7 3 4/378 (1.1) 0/810 (0.0) NA 0.003
B
 
*
 
08 6 3 4/312 (1.3) 28/832 (3.4) 0.4 0.057
B
 
*
 
35 3 2 8/108 (7.4) 0/684 (0.0) NA
 
 
 
 0.001
B
 
*
 
37 5 1 20/80 (25.0) 8/272 (2.9) 8.5
 
 
 
 0.001
B
 
*
 
44 7 1 0/126 (0.0) 2/270 (0.7) 0
 
 
 
 
 
0.10
 
Proportion of amino acid substitutions in known epitopes located in HCV Core, p7, NS2, and NS3, according to the presence or absence of the associated HLA allele (28).
Epitopes were considered in the region sequenced (corresponding to amino acid residues 1–1651 of the H77 polyprotein (GenBank/EMBL/DDBJ accession no. AF009606). Two 
sequences per subject were examined. P values were calculated by comparison of proportions as implemented in SigmaStat (Systat Software, Inc.). NA means not applicable due 
to zero cell. EpiChanges, a software program created by S.C. Ray to automate this analysis, is available from the author. 
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creased risk of mutations from the inoculum occurred when
the restricting allele was present), there was also an increased
number of changes away from the 1b prototype consensus in
women with one of these alleles, but not those without (Ta-
ble II). In addition, for epitopes that showed the converse ef-
fect, i.e., evidence of positive selection when the allele was
absent (a significantly lower risk of mutations from the inoc-
ulum when the restricting allele was present), there was also
an increased number of changes toward consensus in those
who lacked the allele versus those who had the allele, sug-
gesting reversion (Table II). These findings are supported by
an accompanying report, Cox et al. (11), which shows that
amino acid substitutions in CD8
 
 
 
 T cell epitopes are associ-
ated with a loss of T cell recognition during acute infection,
whereas nonepitope changes revert toward consensus at a
rate much higher than expected by chance.
The persistence of R at position 1397 in half of the
B*08-negative women suggests an alternative hypothesis,
namely that reversion is a neutral process. If that were true,
then R at position 1397 would be expected in about half of
all B*08-negative HCV-infected persons; however, 82 of 83
subtype 1b reference sequences have K at position 1397. It is
highly unlikely that HLA B*08 was present in more than
half of the persons from whom the reference sequences were
obtained; therefore, the available evidence does not support
the hypothesis that R versus K at position 1397 is neutral
(random). A similar phenomenon of delayed reversion has
been observed in the setting of primary infection with drug-
resistant HIV-1, suggesting that this is a complex process,
and compensatory mutations may play a role. (12)
Indirectly, these results suggest that immune escape is
costly to the virus. Fitness is conventionally measured as a
competition among genetic variants, and when the viral pop-
ulation size is large the most successful variants present at any
one time in a host are by definition the most fit under the
overall selection pressures. We assume that over very long pe-
riods of time (relative to the viral life cycle) the residues in the
viral genome have the opportunity to vary substantially, and
independently to a first approximation (this is a fundamental
assumption of phylogenetic analysis). Therefore, although
there may be some covariation, analytically the positions in
the sequence can be considered independent variables. Find-
ing a strong positive correlation between the presence of HLA
alleles and substitutions in allele-associated epitopes suggests
that those changes increase viral fitness in the presence of the
associated immune response. Likewise, a strong association
between the absence of alleles and substitutions in allele-asso-
ciated epitopes, particularly when found to represent reversion
 
Figure 3. Escape versus reversion in the presence versus absence of 
the restricting HLA allele.
 
 (A) Amino acid alignment of a region in NS3 
(positions 1388 to 1431 relative to the H77 polyprotein (GenBank/EMBL/
DDBJ accession no. AF009606) showing sites with polymorphism. Study 
subjects are listed in arbitrary order. Identity to the inoculum sequence 
(“inoc”) is indicated by “.”. (B) Sorting the subjects by the presence of HLA 
A*02, G1409S substitution in the 4th position of a frequently recognized 
HLA A*02-restricted epitope at 1406–1415 is limited to subjects having 
the HLA A*02 allele. The subtype 1b consensus sequence for this epitope is 
shown below the alignment, and has been shown to be recognized as 
readily as the prototype (subtype 1a) KLVALGINAV sequence (27). Subject 
AD17 (HLA A*01, A*11) had G1409D substitution, the impact of which on 
recognition is unknown. (C) Variation resulting in reversion to a HLA B*08-
restricted epitope. Sorting the subjects by presence of HLA B*08, R1397K 
substitution in the 3rd position of a frequently recognized HLA B*08-
restricted epitope at 1395–1403 is limited to subjects lacking the HLA 
B*08 allele. The inoculum sequence differs from the prototypical epitope 
(HSKKKCDEL) at the 3rd position. Reversion to consensus (and the proto-
type epitope) occurred only in study subjects lacking the HLA B*08 allele. 
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to consensus, suggests that positive selection in a previous host
carried a fitness cost in terms of viral replicative capacity.
Prior studies have demonstrated reversion of CTL es-
cape–variant sequences in macaques experimentally infected
with SIV (13), reversion of one epitope each of HIV-1 and
HCV in humans (14, 15), and evidence of HIV-1 adaptation
to common HLA alleles (16). This is the first report of viral
adaptation to multiple HLA alleles across multiple genes in
HCV, and provides additional support for the suggestion,
based on minimizing differences between vaccine and circu-
lating strains, that vaccine effectiveness may be enhanced by
using a consensus (17) or ancestral (18) sequence.
The ability of viruses to restrict adaptive immune re-
sponses and evade those that are formed contributes to per-
sistence and is a major barrier to vaccine development.
These data suggest that escape variants have greater fitness in
the presence of an individual host’s immune response, and
that immune evasion contributes to the sequence divergence
observed in a each persistently infected host. Nonetheless,
this divergence may actually reduce the fitness of the virus in
the population (that is, in other hosts). From an evolutionary
perspective, these forces maintain the virus as a distinct
pathogen. However, the data also suggest that immune re-
sponses to consensus sequences (rather than a product based
on the sequence in a given host) may establish the highest
barrier to viral escape and consequently the most effective
protection against chronic infection.
 
MATERIALS AND METHODS
 
Study subjects.
 
22 women from this outbreak were studied because speci-
mens were available, they provided consent, their HLA class I genotyping
was complete, and they had at least one of the three most common A gene
alleles (A*01, A*02, or A*03; reference 19). Informed consent was obtained
from the subjects studied and the research protocol was approved by the
Cork University Hospital Ethics Committee. Work performed in Baltimore
was approved by the Johns Hopkins Medicine Institutional Review Board.
 
Hemigenomic cDNA cloning.
 
The region encoding Core, E1, E2, p7,
NS2, and NS3 was amplified and cloned as previously described (20), and
40 clones per specimen were stored. For each specimen, envelope se-
quences from 10 random randomly selected clones were determined using
primer H77-1868a21 (20) on a PRISM version 3100 sequencer (ABI).
These sequence data are available from GenBank/EMBL/DDBJ under ac-
cession nos.
 
 
 
DQ061331 through DQ061378.
 
Estimation of consensus sequence.
 
An alignment of full-length HCV
subtype 1b sequences was obtained from the Los Alamos National Labora-
tories HCV database (http://hcv.lanl.gov). The alignment was edited by
hand to remove gaps introduced for alignment to other genotypes, and to
remove duplicate sequences from the same human source and those ob-
tained from nonhuman sources. The resulting alignment included 83 se-
quences. A majority-rule consensus sequence was formed, with residues oc-
curring in less than 42 sequences flagged as nonconsensus. Changes in the
anti-D recipients were then classified as “toward” (change results in a resi-
due matching the consensus) or “away” (change results in a residue not
matching the consensus, or residue is nonconsensus).
 
Estimation of the likelihood of convergence.
 
The expected fre-
quency of covariation assuming independence was calculated as the product
of the marginal frequencies, and compared with the observed value using
the Chi-squared distribution with three degrees of freedom.
If we assume that all amino acid replacements are equally likely over a
time period that is very long with respect to the rate of mutation, then shar-
ing of amino acids at four variable sites in just two study subjects would be
expected to occur at a frequency of 1/20
 
4
 
 or 0.00000625. Of course, all
amino acid replacements are not equally likely, even in the highly variable
HVR1 (8); therefore, the likelihood of sharing of four variable sites by two
subjects would be higher, e.g., 1/3
 
4
 
 or 0.012 if each site is equally likely to
have one of three residues. Because the likelihood of shared residues at vari-
able sites in multiple study subjects is the product of such probabilities, the
observed findings in this study are clearly incompatible with random substi-
tution and most consistent with convergent evolution.
 
Phylogenetic analysis.
 
Sequences were aligned using ClustalX (21),
codon boundaries were restored by hand in BioEdit (22), and phylogenetic
analysis was performed using PAUP* version 4b10 (Sinauer Associates) using
a HKY85
 
 
 
G model and parameters (Ti/Tv 2.78, 
 
 
 
 
 
  
 
0.37) selected with
the aid of ModelTest (23). Initial results from one specimen were consistent
with subtype 1a, and that specimen was not examined further. Reference se-
quences included 3 from subtype 1a, 83 from subtype 1b (including
AF313916), 2 from subtype 1c, 6 from subtype 2a, 8 from subtype 2b, 1 each
from subtypes 2c and 2k, 4 from subtype 3a, and 1 each from subtypes 3b,
3k, 4a, 5a, 6a, 6b, 6d, 6g, 6h, and 6k (obtained from http://hcv.lanl.gov).
 
Table II.
 
Classification of amino acid substitutions in MHC class I–restricted epitopes as being toward or away from a 1b 
consensus sequence in 22 women exposed to a common HCV subtype 1b inoculum
 
Effect of allele presence 
on likelihood of amino 
acid replacement Changes in epitopes relative to 1b consensus per 1,000 sites
Allele present Allele absent
Toward consensus Away from consensus Toward consensus Away from consensus
 
566 sites 1,766 sites
Increased relative risk
(B
 
*
 
07, B
 
*
 
35, B
 
*
 
37) 
0.0 56.5
 
a
 
0.0 4.5
510 sites 1,030 sites
Decreased relative risk
(A
 
*
 
01, B
 
*
 
08)
3.8 4.7 22.3
 
a
 
4.8
 
Results are stratified (in columns) by the presence or the absence of the relevant allele, and grouped (rows) according to relative risk for change shown in Table I. Changes are 
per 1000 epitope sites, based on whether the resulting residue matches HCV 1b consensus.
 
a
 
P 
 
 
 
 0.001 for comparison of toward versus away. 
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VarPlot was used to calculate nonsynonymous and synonymous dis-
tances using the method of Nei and Gojobori, in a sliding window 20
codons wide, moving in 1 codon steps, as previously described (24).
 
Sequence logos.
 
A sequence logo is a graphical representation of a group
of aligned sequences, at each position of which the frequency of each resi-
due is represented by the height of the single-letter representation of that
residue (25). The sequence logos in Fig. 2 were generated using a novel
software program, VisSPA (Visual Sequence Pattern Analysis, available on
request from the author S.C. Ray). The algorithm is identical to that de-
scribed for type 2 logos by Gorodkin et al. (26), except that the a priori dis-
tributions for the logo are calculated empirically from input sequences, and
missing values in the a priori distribution are assigned the lowest frequency
of residues at that site (if more than one state is represented) or 1/20 if the a
priori distribution has only one residue at that site.
 
Online supplemental material.
 
Fig. S1 shows the variability of HVR1 in
each study subject. Fig. S2 shows the sequences at the sites of known MHC
class I–restricted alleles in each study subject. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20050122/DC1.
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